Japanese Encephalitis Virus Vaccine (Inactivated)
- Atc Codes:J07BA02
Table of contents
- Brand Names
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
Brand Names
Europe
Austria: Ixiaro; Belgium: Ixiaro; Bulgaria: Ixiaro; Czech Republic: Ixiaro; Denmark: Ixiaro; Estonia: Ixiaro; Finland: Ixiaro; France: Ixiaro; Germany: Ixiaro; Ireland: Ixiaro; Latvia: Ixiaro; Lithuania: Ixiaro; Luxembourg: Ixiaro; Malta: Ixiaro; Netherlands: Ixiaro; Poland: Ixiaro; Portugal: Ixiaro; Romania: Ixiaro; Slovakia: Ixiaro; Slovenia: Ixiaro; Spain: Ixiaro; Sweden: Ixiaro; UK: Ixiaro.
North America
Canada: JE-Vax; USA: Ixiaro, JE-Vax.
Asia
Japan: Japanese Encephalitis Vaccine.
Drug combinations
Chemistry
Pharmacologic Category
Serums, Toxoids, and Vaccines; Vaccines. (ATC-Code: J07BA02).
Mechanism of action
Japanese encephalitis virus vaccine is a lyophilized preparation of inactivated Japanese encephalitis virus which stimulates active immunity to infection by virus.
Therapeutic use
Active immunization against Japanese encephalitis.
Pregnancy and lactiation implications
Pregnant women should only be vaccinated if they are at high risk for exposure. Infection from Japanese encephalitis during the 1^st^ or 2^nd^ trimesters of pregnancy may increase risk of abortion.
Unlabeled use
Contraindications
Hypersensitivity to Japanese encephalitis virus vaccine. Hypersensitivity to any component of vaccine including proteins of rodent or neural origin. Hypersensitivity to thimerosal.
Warnings and precautions
Possible anaphylactoid or hypersensitivity reactions. Severe adverse reactions (generalized urticaria or angioedema) might occur. Use with caution in severe allergies to other medications. Use caution with significant history of urticaria following exposure to insect stings (increased risk of adverse events). Use with caution in severely immunocompromised patients (may have reduced response to vaccination).